Mettler-Toledo (MTD) Receives a Buy from Barclays
In a report released today, Luke Sergott from Barclays maintained a Buy rating on Mettler-Toledo, with a price target of $1,500.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Sergott is an analyst with an average return of -2.6% and a 37.95% success rate. Sergott covers the Healthcare sector, focusing on stocks such as 10x Genomics, Charles River Labs, and Sotera Health.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mettler-Toledo with a $1,451.33 average price target.
Based on Mettler-Toledo’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.13 billion and a net profit of $285.77 million. In comparison, last year the company earned a revenue of $1.05 billion and had a net profit of $252.3 million
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MTD in relation to earlier this year. Most recently, in February 2026, Shawn Vadala, the CFO of MTD sold 800.00 shares for a total of $1,128,096.00.
Read More on MTD:
